Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Abstract

The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).